A bill to amend the Pharmaceutical and Medical Devices (PMD) Law is expected to be submitted to the ordinary session of the Diet this year, which was convened on January 17 for a 150-day run. The proposed amendment is for…
HOME > COMMENTARY
COMMENTARY
-
COVID-19’s Impact on Pharma Becoming Clearer with New Data, Earnings
August 17, 2020
-
With Equivocal Honebuto Wording, Off-Year Re-Pricing Debate Delayed Until Year-End
July 30, 2020
-
Japan to See Arrival of 1st Treatment for HFpEF, Will Entresto Meet Unmet Medical Needs?
July 22, 2020
-
Diabetes Market Regaining Momentum with New Launches; First Oral GLP-1 a Game Changer?
July 13, 2020
-
Will Zolgensma Delay Spur Revision of Sakigake Designation System?
June 11, 2020
-
Establish Development Regime to Always Be Prepared for New Infectious Disease, Global Health Confab Urges amid COVID-19
May 7, 2020
-
Blurred Outlook for Off-Year Drug Re-Pricing, Will Japan Go Ahead with April 2021 Plan?
April 27, 2020
-
Drug Rep Number Might Have Logged 5,000-Plus Decrease in 1 Year: Jiho Tally
April 22, 2020
-
Lenvima Heading into Megablockbuster Territory, Will Merck Tie-Up Help It Top Combined Aricept/Pariet Sales?
March 12, 2020
-
Unison Capital Shows Rising Presence with Kyowa Deal, PE Fund Potential Catalyst for Industry Shakeup?
November 22, 2019
-
Finance Officials, Payers Grow Jittery as Xolair’s Pollen Allergy Nod Looms
November 18, 2019
-
Pharma’s Downsizing Bandwagon Shows No Sign of Slowing, Companies Seeking Even Leaner Staff
October 28, 2019
-
Pharma Should Tap Health Coverage Debate as Catalyst to Draw Govt’s Commitment on Innovation
October 1, 2019
-
After Death in First-in-Human Study, MHLW Needs to Release Info. to Alleviate Concerns about Participation in Studies
August 26, 2019
-
Generic Players Step Up Info Disclosure for Survival in Post-80% Era
July 16, 2019
-
Drug Pricing Debate for 2020 Reform Going into High Gear; Industry Leery of Post-Election Surprises
July 5, 2019
-
Filing for Sakigake Radiation Therapy Expected This Year for Head and Neck Cancer; Expanded Use, Overseas Development Eyed
June 25, 2019
-
Cell Therapy Makers Working to Stand Out from Rivals by Reducing Burdens on Hospitals
April 16, 2019
-
Building Credible, Convincing System Holds Key for Japan’s Cost-Effectiveness Assessment
April 2, 2019
-
Generic Makers Shifting to Focus on “Specialty Area” Faced with Tougher Business Environment
March 4, 2019
ページ
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…
Japan’s all-important reimbursement policy panel on December 22 approved an outline of the next drug pricing reform scheduled for April 2022, which embraces plans to reward innovative new indications and introduce a grace period for so-called “spillover” re-pricing.The reform outline…
Remember what it was like back in March, when we all started working from home? There was a distinct change in the air - a sense of freedom and excitement about the novelty of being able to work from home.…
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…